Dossier
GLP-1 obesity drugs
Coverage of GLP-1 obesity drugs in the Nexus archive.
- Roundup: Delta’s new fare / Fed meeting minutes / GLP-1 coverage
Delta Air Lines is introducing a lower-cost business-class fare with fewer perks, the Federal Reserve's June meeting minutes revealed divided views on interest rates, and many employers are delaying expanded coverage for GLP-1 obesity drugs due to rising healthcare costs.
- Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs – many are finding ways around it
Approximately 36% of employers provide coverage for GLP-1 obesity drugs for both diabetes and weight loss in 2025, unchanged from the previous year and up from 34% in 2024. Many employers are finding ways to avoid expanding this coverage.